Fresenius SE & Co KGaA (FRA:FRE) received a €70.00 ($81.40) price target from investment analysts at Cfra in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the stock. Cfra’s target price indicates a potential upside of 22.85% from the stock’s previous close.
A number of other research firms have also recently weighed in on FRE. UBS Group set a €57.00 ($66.28) price objective on Fresenius SE & Co KGaA and gave the company a “sell” rating in a research report on Monday, August 6th. DZ Bank reissued a “buy” rating on shares of Fresenius SE & Co KGaA in a report on Tuesday, August 7th. Deutsche Bank set a €82.00 ($95.35) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Thursday, July 19th. Warburg Research set a €80.00 ($93.02) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Thursday, October 4th. Finally, Sanford C. Bernstein set a €83.00 ($96.51) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Monday, July 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of €75.94 ($88.31).
Shares of FRE stock traded down €0.08 ($0.09) during trading hours on Wednesday, reaching €56.98 ($66.26). 1,005,227 shares of the company traded hands. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02).
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
Further Reading: What are the economic characteristics of a bear market?
Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.